LDLeslie J. Donato

Leslie J. Donato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leslie J. Donato has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From Pooled Cohorts to PREVENT: A Perspective for Clinical Laboratorians

    by Ryan Pearce, Leslie J Donato, Vlad C Vasile, Allan S Jaffe, Jeffrey W Meeusen

  • Open Access

    Benchmarking Institutional Support for Point-of-Care Testing Programs: Scale, Staffing, and Operational Challenges

    by Min Yu, Nam K Tran, Julie L V Shaw, Nicholas E Larkey, Nicole V Tolan, Andrew Szczembara, Leslie J Donato, Robert D Maynard, Adil I Khan

    Background: Point-of-care testing (POCT) has expanded rapidly across healthcare systems, increasing both program scale and operational complexity. However, quantitative benchmarking data describing how POCT programs are structured and supported across institutions remain limited. Methods: We conducted a cross-sectional survey to characterize POCT program support, including program scope, staffing, operational practices, governance, and challenges. The survey was distributed electronically through professional networks, and 93 institutional responses were analyzed. Descriptive analyses were performed, and derived metrics, including sites per point-of-care testing coordinator (POCC), were used to evaluate the relationship between program scale and staffing. Results: POCT programs demonstrated substantial variability in scale, with wide ranges in the number of testing sites and operator populations. Adoption spanned multiple test categories, and many institutions reported use of multiple platforms for the same assays. Training, competency assessment, and quality management activities were primarily supported by laboratory staff and POCCs, with documentation frequently partially electronic. Median POCC staffing increased with program size; however, sites per POCC also increased significantly across program scale tiers (Kruskal–Wallis P < 0.001). Governance structures and operational responsibilities varied across institutions, and common challenges included staffing limitations, training and compliance burden, multisite coordination, and IT/connectivity constraints. Conclusions: POCT programs are expanding in scale and complexity, but workforce capacity and governance structures have not scaled proportionally. This mismatch creates a cumulative and multiplicative operational burden. These findings provide benchmarking data to inform scalable staffing models, governance strategies, and infrastructure development for sustainable POCT program management.

  • Open Access

    Method Validation of Dipeptidyl Peptidase 3 Assay

    by Leslie J Donato, Jeffrey W Meeusen, Renee’ J Scott, Vlad C Vasile, Allan S Jaffe

    Background: Dipeptidyl peptidase 3 (DPP3) is a peptidase released from dying cells. It cleaves proteins in the renin–angiotensin pathway, which can result in hemodynamic instability. At elevated concentrations DPP3 is associated with worse outcomes, particularly in patients with shock. Herein we describe the assay performance of a DPP3 assay (4TEEN4 Pharmaceuticals GmbH) in human plasma. Methods: DPP3 concentration was measured using the DPP3 immunoluminometric assay (4TEEN4 Pharmaceuticals GmbH) and the signal was read using a luminometer (Berthold Centro LB963). Analytical performance was established for precision, linearity, accuracy, detection limit, analytical specificity, reference interval, kit lot-to-lot comparison, specimen type, and sample stability. Results: Limit of detection was verified at 1.6 ng/mL in EDTA plasma with a coefficient of variation (CV) of <10%. Precision studies revealed a CV ≤ 6% at 28.5 ng/mL and 59.4 ng/mL and comparability with a manufacturer performed assay was demonstrated between 7.7 and 195.2 ng/mL. An upper 97.5% limit of 22 ng/mL without age or sex associations was verified in healthy donors. The assay was not susceptible to interference from lipemia or bilirubin. However, measured DPP3 concentrations increased linearly with increasing hemolysis. DPP3 concentrations are stable in EDTA plasma for up to 24 h and at least 11 months when stored ambient or at −80°C, respectively. Conclusions: DPP3 can be measured precisely in EDTA plasma using the immunoluminometric DPP3 assay. Given the potential clinical use of DPP3 in critical care patients, caution should be taken to avoid inducing pre-analytical hemolysis during sample collection.


  • Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol

    by Jeffrey W Meeusen, Xin Yi, Steven W Cotten, Jacob B Nielsen, Leslie J Donato, Patricia M Jones, Alagar R Muthukumar, Rafael Zubirán, Alan T Remaley, Jing Cao

    Background: Direct measurement of low-density lipoprotein cholesterol (LDL-C) is widely used and recommended by professional society guidelines despite its potential limitations in patients with hypertriglyceridemia and low LDL-C. This study evaluated the performance of 3 direct LDL-C (LDL-CD) assays, 2 modern LDL-C calculation methods [LDL-C Martin (LDL-CM), LDL-C modified Sampson (LDL-CS)] and the conventional Friedewald (LDL-CF) method against the reference method, beta-quantification (LDL-CBQ). Methods: A total of 181 remnant sera from patients with standard lipid panel orders or from patients with LDL-CBQ orders with triglycerides (TG) ≥ 400 mg/dL (4.5 mmol/L), or with TG ≥ 150 mg/dL (1.69 mmol/L) and LDL-C < 70 mg/dL (1.8 mmol/L) were included. LDL-CD and lipid panel data were gathered from Abbott Alinity, Roche Cobas, and Siemens Atellica platforms. Results: LDL-CD among the 3 platforms showed a median CV of 11.2%. In patients with TG <400 mg/dL, LDL-CM and LDL-CS demonstrated less bias and less misclassification at the clinical decision LDL-C levels than LDL-CF or LDL-CD. In the 400 to 800 mg/dL (9.0 mmol/L) TG group, LDL-CS was superior to LDL-CD or LDL-CM in accuracy. When TG is ≥ 800 mg/dL, LDL-CD (Roche) showed substantial bias from LDL-CBQ while LDL-CS (Roche) showed smaller but significant bias. Conclusions: In summary, LDL-CD or LDL-CF showed little advantage over the 2 modern LDL-C calculation methods. LDL-CS showed the best overall correlation with LDL-CBQ and therefore is recommended to replace LDL-CF and potentially LDL-CD when making clinical decisions in patients with low LDL-C and hypertriglyceridemia.


  • Optimal Target of Activated Clotting Time During PCI and Outcomes: The OPTIMAL-ACT Trial

    by S. Michael Gharacholou, Colleen S. Thomas, David O. Hodge, Abdallah El Sabbagh, Gary E. Lane, Peter M. Pollak, Dilip P. Pillai, Gretchen Johns, Leslie J. Donato, Mandeep Singh

  • Lipid Ratio Plot: A Simple Graphical Approach for Investigating the Accuracy of LDL Cholesterol Equations or Direct Assays

    by Thando Gcingca, Maureen Sampson, Rafael Zubirán, Anna Wolska, Jeffrey Meeusen, Leslie Donato, Allan Jaffe, Alan Remaley

    Background: β-Quantification (BQ) is the reference method for low-density lipoprotein cholesterol (LDL-C) determination. It is not widely available, making it challenging for laboratories to assess the accuracy of LDL-C methods. Our goal was to develop an indirect graphical approach for comparing LDL-C test results to the BQ reference method. Methods: BQ results from Mayo Medical Laboratories (n = 39 969) and the National Institutes of Health (n = 17 825) were used to investigate the interrelationships between lipid panel tests. A plot of LDL-C/non high-density lipoprotein cholesterol (nonHDL-C) vs (triglyceride (TG)/nonHDL-C)0.5 (lipid ratio plot) resulted in a negative linear regression line (y = −34.2x + 115). Based on simulation analysis, the minimum sample size for calculating its slope and intercept with a coefficient of variation of about 7.5% was 80. Results: The regression lines for the lipid ratio plot of LDL-C calculated by the Sampson–NIH (y = −37.6x + 118) and enhanced Sampson–NIH (y = −33.1x + 116) equations closely overlapped with the BQ method. In contrast, the Martin–Hopkins equation showed a positive bias with an increasing TG/nonHDL-C ratio and exceeded the recommended bias limit of 4% on hypertriglyceridemic samples (y = −25.5x + 107). The Friedewald equation showed an even larger negative bias with hypertriglyceridemia (y = −47.5x + 126). Lipid ratio plots of the Roche direct assay revealed a fixed positive bias of approximately 4% (y = −33.9x + 120), whereas a much larger proportional positive bias was observed with increasing triglycerides for the Beckman direct assay (y = −14.6x + 97.8). Conclusions: The lipid ratio plot is a simple graphical approach that can be readily performed by clinical laboratories for investigating the accuracy of LDL-C assays by calculation methods or direct assays.


  • Discrepant Risk Assessment between Low-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Size

    by Nicholas E Larkey, Leslie J Donato, Allan S Jaffe, Vlad C Vasile, Jeffrey W Meeusen

    Background: Low-density lipoprotein cholesterol (LDL-C) is directly associated with coronary artery disease (CAD) risk. Subfractionation of LDL enables differentiation between large-buoyant LDL (>20.5 nm) and small-dense LDL (≤20.5 nm). Small-dense LDL reportedly increases CAD risk, as do LDL-C and LDL particle (LDL-P) concentrations. Nuclear magnetic resonance spectroscopy (NMR) reports LDL-C, LDL-P, and LDL size (LDL-s). We investigated associations between these outputs and their agreement on CAD risk information. Methods: Associations between LDL-P, LDL-C, and LDL-s measured by NMR were evaluated in serum from clinically ordered samples (n = 26 710), and a subset of patients with CAD evaluation from coronary angiography (n = 356). Correlations were determined using Spearman ρ, and clinical classifications were compared using the following thresholds for increased risk: LDL-C > 160 mg/dL, LDL-P > 1600 nmol/L, and LDL-S < 20.5 nm. Results: The large laboratory NMR data set showed LDL-C was highly correlated with LDL-P (ρ = 0.87), and moderately with LDL-s (ρ = 0.51). Correlation between LDL-P and LDL-s was weakest (ρ = 0.21). When comparing pairwise high- and low-risk laboratory values, concordant values were observed in 99.8%, 43%, and 25% of cases for LDL-P/LDL-C, LDL-s/LDL-P, and LDL-C/LDL-s, respectively. In patients with angiography and NMR results, CAD was diagnosed in 40% (6/15) of patients with concordant high-risk LDL-C and small-dense LDL-s in the smaller patient cohort, but only 19% (6/31) of CAD-positive patients with high-risk LDL-C had small-dense LDL-s. Conclusions: LDL-s and LDL-C are frequently discordant at established LDL-C risk cutoffs. CAD diagnosis was found in similar numbers regardless of LDL-s phenotype.

  • Su1361 CHARACTERIZATION OF FECAL FAT AND BILE ACID EXCRETION IN PATIENTS WITH ILEAL RESECTIONS OF > OR < 100 CM LENGTH

    by Joelle BouSaba, Lehar Khanna, Priya Vijayvargiya, Leslie J. Donato, Michael Camilleri

  • Open Access

    Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol

    by Weili Zheng, Michael Chilazi, Jihwan Park, Vasanth Sathiyakumar, Leslie J. Donato, Jeffrey W. Meeusen, Mariana Lazo, Eliseo Guallar, Krishnaji R. Kulkarni, Allan S. Jaffe, et al.

    Background: Accurate measurement of the cholesterol within lipoprotein(a) (Lp[a]‐C) and its contribution to low‐density lipoprotein cholesterol (LDL‐C) has important implications for risk assessment, diagnosis, and treatment of atherosclerotic cardiovascular disease, as well as in familial hypercholesterolemia. A method for estimating Lp(a)‐C from particle number using fixed conversion factors has been proposed (Lp[a]‐C from particle number divided by 2.4 for Lp(a) mass, multiplied by 30% for Lp[a]‐C). The accuracy of this method, which theoretically can isolate “Lp(a)‐free LDL‐C,” has not been validated. Methods and Results: In 177 875 patients from the VLDbL (Very Large Database of Lipids), we compared estimated Lp(a)‐C and Lp(a)‐free LDL‐C with measured values and quantified absolute and percent error. We compared findings with an analogous data set from the Mayo Clinic Laboratory. Error in estimated Lp(a)‐C and Lp(a)‐free LDL‐C increased with higher Lp(a)‐C values. Median error for estimated Lp(a)‐C <10 mg/dL was −1.9 mg/dL (interquartile range, −4.0 to 0.2); this error increased linearly, overestimating by +30.8 mg/dL (interquartile range, 26.1–36.5) for estimated Lp(a)‐C ≥50 mg/dL. This error relationship persisted after stratification by overall high‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol subtypes. Similar findings were observed in the Mayo cohort. Absolute error for Lp(a)‐free LDL‐C was +2.4 (interquartile range, −0.6 to 5.3) for Lp(a)‐C<10 mg/dL and −31.8 (interquartile range, −37.8 to −26.5) mg/dL for Lp(a)‐C≥50 mg/dL. Conclusions: Lp(a)‐C estimations using fixed conversion factors overestimated Lp(a)‐C and subsequently underestimated Lp(a)‐free LDL‐C, especially at clinically relevant Lp(a) values. Application of inaccurate Lp(a)‐C estimations to correct LDL‐C may lead to undertreatment of high‐risk patients.